$XBI $90.79 | +1.5%
Covid Updates
$NVAX +1.0% - New Zealand's Medsafe Grants Provisional Approval for Novavax' COVID-19 Vaccine. source
Pipeline Updates
$OBSV +3.6% - ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids. source
$CYTK +5.0% - FDA Acceptance of New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure With Reduced Ejection Fraction. source
$TLSA -3.2% - Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn’s Disease. source
$VNDA -17.9% - Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis. source
$ACIU +1.5% - ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease. source
$HCM +1.5% - HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China. source
Business Updates
$ORTX +7.6% - Orchard Therapeutics Announces Historic Agreement Making Libmeldy Available by NHS England for MLD Patients. source
Posted by DV/FS
Comentários